Company Overview

Charles River Laboratories International, Inc. is a global contract research organization (CRO) that provides essential products and services to support the discovery, development, and manufacturing of new drugs, biologics, and medical devices. The company operates primarily within the biopharmaceutical, biotechnology, medical device, and academic research industries, serving clients across the entire research and development lifecycle from early discovery through preclinical and clinical support.

The company’s primary revenue drivers include research models and services, preclinical drug discovery and safety assessment services, and manufacturing support solutions for advanced therapies. Charles River is positioned as a critical outsourcing partner for pharmaceutical and biotechnology companies, offering integrated capabilities that reduce development timelines and regulatory risk. Founded in 1947 as a laboratory animal supplier, the company has evolved through organic growth and acquisitions into a diversified global CRO with a strong emphasis on scientific expertise, regulatory compliance, and scale.

Business Operations

Charles River operates through three primary business segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (MS). RMS provides laboratory animals, related services, and research support products that underpin early-stage biomedical research. DSA delivers integrated discovery, pharmacology, toxicology, and safety testing services that support preclinical development and regulatory submissions. MS focuses on cell and gene therapy testing, viral clearance, biologics testing, and contract manufacturing support.

The company conducts operations across both domestic and international markets, with facilities in North America, Europe, and Asia-Pacific. Charles River controls specialized laboratory infrastructure, proprietary research platforms, and regulated manufacturing and testing facilities. Its operating model relies on long-term client relationships, recurring service contracts, and embedded partnerships within client R&D workflows, particularly with large pharmaceutical companies and emerging biotechnology firms.

Strategic Position & Investments

Charles River’s strategic direction centers on expanding its role as an end-to-end partner for complex and regulated research activities, particularly in cell and gene therapy, biologics, and advanced therapeutic modalities. Growth initiatives include capacity expansion in high-demand testing services, integration of digital and data-driven research tools, and continued investment in regulated manufacturing and quality systems.

The company has pursued targeted acquisitions to strengthen its scientific capabilities and geographic reach, including Cognate BioServices, HemaCare, and Retrogenix, which enhanced its manufacturing solutions, cell therapy capabilities, and biologics discovery platforms. Charles River maintains a portfolio of specialized subsidiaries aligned with its operating segments, enabling it to offer vertically integrated solutions that are difficult for smaller competitors to replicate.

Geographic Footprint

Charles River is headquartered in North America, with its corporate headquarters located in Wilmington, Massachusetts. The company maintains a broad operational presence across North America, Europe, and Asia-Pacific, supporting both local and global research programs for multinational clients.

Its facilities span the United States, Canada, Western and Central Europe, China, Japan, and other parts of Asia, allowing the company to meet regional regulatory requirements and provide proximity to major life sciences hubs. This global footprint supports international clinical development, cross-border regulatory submissions, and supply chain resilience for critical research services.

Leadership & Governance

Charles River is led by an executive team with deep experience in life sciences, regulated research, and global operations. The leadership emphasizes scientific rigor, regulatory compliance, ethical research practices, and long-term value creation through strategic investment and operational excellence.

Key executives include:

• James C. Foster – Chair, President, and Chief Executive Officer
• David R. Smith – Chief Financial Officer
• Birgit Girshick – Chief Operating Officer
• Bradley K. Bolton – Chief Scientific Officer
• Alicia S. Secor – Corporate Executive Vice President and General Counsel

The company operates under a governance framework aligned with U.S. public company standards, with oversight by an independent board of directors and a focus on compliance with global regulatory and ethical research requirements.